Halozyme Therapeutics Inc

HALO

NASDAQ. Currency in USD

55.94 -3.50 ( -5.89% )

Real time prices: December 05

Market Cap.
7.56B
Beta (5Y monthly)
1.22
Price/Earnings
25.16
EPS (TTM)
2.16
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
2.35M
1y Target Est.
53.22
Day's Range
55.42
-
59.33
52 Week's Range
31.36
-
59.46

Historical Summary

Performance
EPS growth
Share Buybacks

About Halozyme Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.halozyme.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
140.79M
Employees
145
Address
11388 Sorrento Valley Road, San Diego, CA, United States, 92121
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Latest news

Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022

Upgrades Barclays upgraded the previous rating for PerkinElmer Inc (NYSE:PKI) from Underweight to Equal-Weight. For...
By Benzinga - 1 week ago

Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why

Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues...
By Zacks Investment Research - 1 week ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than...
By Zacks Investment Research - 1 week ago

4 Analysts Have This to Say About Halozyme Therapeutics
4 Analysts Have This to Say About Halozyme Therapeutics

Halozyme Therapeutics (NASDAQ:HALO) has observed the following analyst ratings within the last quarter: Bullish Somewhat...
By Benzinga - 1 week ago

GILD vs. HALO: Which Stock Is the Better Value Option?
GILD vs. HALO: Which Stock Is the Better Value Option?

GILD vs. HALO: Which Stock Is the Better Value Option?
By Zacks Investment Research - 1 week ago

Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina

Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt...
By Benzinga - 3 weeks ago

Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates

Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.
By Zacks Investment Research - 3 weeks ago